Skip to main content

Conclusions

Buy Article:

$32.00 plus tax (Refund Policy)

Abstract:

While research in pharmacogenetics is proceeding rapidly, at the start of 2009 there were only just over a dozen pharmacogeneticsbased products on the market. A number of scientific, economic and regulatory challenges need to be overcome if pharmacogenetics is to be taken up more widely within health‐care systems. It is not yet clear to the private sector what business models will deliver acceptable returns on investment. In the public sector, governments have a number of levers which they could use to create an "enabling" environment for pharmacogenetics, while continuing to provide the necessary checks and balances.

Document Type: Review Article

Publication date: 2009-11-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more